Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Neochamaejasmine A Promotes Apoptosis and Cell Cycle Arrest in B16F10 Melanoma Cells via JNK and p38 MAPK Signaling Pathway

Author(s): Xiaoyu Chen, Wei Zhao, Weiwei Zhu, Lan Yu, Xuejie Zhu, Yangfang Ding and Qiusheng Zheng*

Volume 17, Issue 4, 2022

Published on: 27 April, 2022

Page: [416 - 426] Pages: 11

DOI: 10.2174/1574892817666220114105639

Price: $65

Abstract

Background: The incidence of melanoma has been increasing over the last 30 years. The most common treatments, such as surgery, chemotherapy, and radiotherapy, frequently cause serious damage to the body. It is therefore critical to develop a new therapeutic strategy for the treatment of melanoma.

Objectives: This research aims to evaluate the anti-tumor effect of Neochamaejasmine A (NCA) on B16F10 melanoma cells and the underlying molecular mechanisms.

Methods: The CCK-8 kit was utilized to assay the influence of NCA on the vitality of B16F10 cells. Modifications in B16F10 cells morphology were observed using a phase-contrast microscope. Apoptosis of B16F10 melanoma cells was assessed by Hoechst 33258, Annexin V and propidium iodide staining. Cell cycle was detected using a commercial kit by flow cytometry. The mRNA and protein expression levels associated with apoptosis and cell cycle arrest were detected by RT-PCR and Western blot. The expression level of pathway proteins was assessed using Western blot.

Results: It was found that the proliferation of B16F10 cells was inhibited by NCA in concentration- and time-dependent manners. NCA promoted apoptosis by halting the cell cycle at the G2/M phase. After treatment with NCA, cell apoptosis was confirmed by Hoechst 33258 staining. NCA triggered the cell cycle to seize at the G2/M stage by downregulating cyclin B1 and cyclin-dependent kinase 2 (CDC2) expression. Moreover, the mRNA and protein expression of cleaved caspase- 9 and Bcl-2-associated X-protein (Bax) were increased, whereas there was a decline in the expression of B-cell lymphoma 2 (Bcl-2). The p-p38/p38 and phosphorylated c-Jun N-terminal kinase (p-JNK/JNK) ratio were also elevated by NCA. The apoptosis and G2/M cell cycle arrest were inhibited in cells co-treated with the p38 inhibitor SB203580 and JNK inhibitor SP600125. The expression of apoptosis-related proteins Bax was decreased, and Bcl-2 was increased.

Conclusion: The findings of this study showed that NCA could induce apoptosis and cell cycle arrest in B16F10 melanoma cells by activating JNK and p38 MAPK signaling pathway.

Keywords: Neochamaejasmine A, B16F10 cells, apoptosis, cycle arrest, JNK, p38 MAPK signaling pathway.

« Previous Next »
[1]
Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445(7130): 851-7.
[http://dx.doi.org/10.1038/nature05661] [PMID: 17314971]
[2]
Huynh Thien Duc G, Ed. Davids LK and leemann B. The menace of melanoma: a photodynamic approach to adjunctive cancer therapy. In: Melanoma: From Early Detection to Treatment. Croatia: INTECH Open Access Publisher 2013.
[3]
Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 2005; 23(2): 105-61.
[http://dx.doi.org/10.1080/10590500500234970] [PMID: 16291526]
[4]
Pópulo H, Soares P, Lopes JM. Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets 2012; 16(7): 689-705.
[http://dx.doi.org/10.1517/14728222.2012.691472] [PMID: 22620498]
[5]
Papanikolaou M, Chohan T, Millington GWM. Malignant melanoma, papillary thyroid carcinoma and Erdheim-Chester disease, associated with both BRAFV600E and mosaic Turner syndrome. Clin Exp Dermatol 2020; 45(4): 512-4.
[http://dx.doi.org/10.1111/ced.14153] [PMID: 31875997]
[6]
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6): 1374-403.
[http://dx.doi.org/10.1016/j.ejca.2012.12.027] [PMID: 23485231]
[7]
Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. ImmunoTargets Ther 2018; 7: 35-49.
[http://dx.doi.org/10.2147/ITT.S134842] [PMID: 29922629]
[8]
Li J, Wang Y, Liang R, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine 2015; 11(3): 769-94.
[http://dx.doi.org/10.1016/j.nano.2014.11.006] [PMID: 25555352]
[9]
Huang YY, Vecchio D, Avci P, Yin R, Garcia-Diaz M, Hamblin MR. Melanoma resistance to photodynamic therapy: new insights. Biol Chem 2013; 394(2): 239-50.
[http://dx.doi.org/10.1515/hsz-2012-0228] [PMID: 23152406]
[10]
Haugh AM, Salama AKS, Johnson DB. Advanced melanoma: resistance mechanisms to current therapies. Hematol Oncol Clin North Am 2021; 35(1): 111-28.
[http://dx.doi.org/10.1016/j.hoc.2020.09.005] [PMID: 33759769]
[11]
Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. Arch Dermatol Res 2017; 309(4): 229-42.
[http://dx.doi.org/10.1007/s00403-017-1720-9] [PMID: 28314913]
[12]
Catalani E, Proietti Serafini F, Zecchini S, et al. Natural products from aquatic eukaryotic microorganisms for cancer therapy: perspectives on anti-tumour properties of ciliate bioactive molecules. Pharmacol Res 2016; 113(Pt A): 409-20.
[13]
Tatullo M, Simone GM, Tarullo F, et al. Antioxidant and antitumor activity of a bioactive polyphenolic fraction isolated from the brewing process. Sci Rep 2016; 6: 36042.
[http://dx.doi.org/10.1038/srep36042] [PMID: 27786308]
[14]
Chen JR, Jia XH, Wang H, Yi YJ, Wang JY, Li YJ. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Int J Oncol 2016; 48(5): 2063-70.
[http://dx.doi.org/10.3892/ijo.2016.3423] [PMID: 26984633]
[15]
Appadath Beeran A, Maliyakkal N, Rao CM, Udupa N. The enriched fraction of vernonia cinerea l. induces apoptosis and inhibits multi-drug resistance transporters in human epithelial cancer cells. J Ethnopharmacol 2014; 158(Pt A): 33-42.
[16]
Feng BM, Pei YH, Hua HM. Chemical constituents of Stellera chamaejasme L. J Asian Nat Prod Res 2002; 4(4): 259-63.
[http://dx.doi.org/10.1080/10286020290028992] [PMID: 12450253]
[17]
Ren Y, Mu Y, Yue Y, Jin H, Tao K, Hou T. Neochamaejasmin a extracted from stellera chamaejasme l. induces apoptosis involving mitochondrial dysfunction and oxidative stress in Sf9 cells. Pestic Biochem Physiol 2019; 157: 169-77.
[http://dx.doi.org/10.1016/j.pestbp.2019.03.025] [PMID: 31153465]
[18]
Ding Y, Xie Q, Liu W, et al. Neochamaejasmin A induces mitochondrial-mediated apoptosis in human hepatoma cells via ROS-dependent activation of the ERK1/2/JNK signaling pathway. Oxid Med Cell Longev 2020; 2020: 3237150.
[http://dx.doi.org/10.1155/2020/3237150] [PMID: 32411325]
[19]
Liu WK, Cheung FW, Liu BP, Li C, Ye W, Che CT. Involvement of p21 and FasL in induction of cell cycle arrest and apoptosis by neochamaejasmin A in human prostate LNCaP cancer cells. J Nat Prod 2008; 71(5): 842-6.
[http://dx.doi.org/10.1021/np8001223] [PMID: 18380477]
[20]
Liu J, Chang F, Li F, et al. Palmitate promotes autophagy and apoptosis through ROS-dependent JNK and p38 MAPK. Biochem Biophys Res Commun 2015; 463(3): 262-7.
[http://dx.doi.org/10.1016/j.bbrc.2015.05.042] [PMID: 26002468]
[21]
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9(8): 537-49.
[http://dx.doi.org/10.1038/nrc2694] [PMID: 19629069]
[22]
Liu Y, Song Y, Zhu X. MicroRNA-181a regulates apoptosis and autophagy process in parkinson’s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) signaling pathways. Med Sci Monit 2017; 23: 1597-606.
[http://dx.doi.org/10.12659/MSM.900218] [PMID: 28365714]
[23]
van den Heuvel S. Cell-cycle regulation. In: WormBook. 2005; pp. 1-16.
[PMID: 18050422]
[24]
Stark GR, Taylor WR. Control of the G2/M transition. Mol Biotechnol 2006; 32(3): 227-48.
[http://dx.doi.org/10.1385/MB:32:3:227] [PMID: 16632889]
[25]
Choi SU, Ryu SY, Yoon SK, et al. Effects of flavonoids on the growth and cell cycle of cancer cells. Anticancer Res 1999; 19(6B): 5229-33.
[PMID: 10697540]
[26]
Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000; 12(6): 658-65.
[http://dx.doi.org/10.1016/S0955-0674(00)00149-6] [PMID: 11063929]
[27]
Xie B, Wang S, Jiang N, Li JJ. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett 2019; 443: 56-66.
[http://dx.doi.org/10.1016/j.canlet.2018.11.019] [PMID: 30481564]
[28]
Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37(3): 299-310.
[http://dx.doi.org/10.1016/j.molcel.2010.01.025] [PMID: 20159550]
[29]
Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell Death Differ 2018; 25(1): 37-45.
[http://dx.doi.org/10.1038/cdd.2017.170] [PMID: 29099482]
[30]
Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007; 26(22): 3159-71.
[http://dx.doi.org/10.1038/sj.onc.1210409] [PMID: 17496913]
[31]
Faris M, Kokot N, Latinis K, et al. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol 1998; 160(1): 134-44.
[PMID: 9551965]
[32]
Zhang Y, Wu Q, Zhang L, et al. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson’s disease. Pharmacol Res 2019; 150: 104538.
[http://dx.doi.org/10.1016/j.phrs.2019.104538] [PMID: 31707034]
[33]
Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol 2013; 87(7): 1157-80.
[http://dx.doi.org/10.1007/s00204-013-1034-4] [PMID: 23543009]
[34]
Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000; 275(18): 13690-8.
[http://dx.doi.org/10.1074/jbc.275.18.13690] [PMID: 10788488]
[35]
Zhang JK, Hu ZM, Zhang JS. Extraction technology of neochamaejasmine A. CN 02133768,

Rights & Permissions Print Cite
Article Metrics
34
2
© 2024 Bentham Science Publishers | Privacy Policy